PREvention of Cardiovascular and DiabEtic kidNey disease in Type 2 Diabetes (PRECIDENTD)

PI(s): Brendan Everett and Robert J. Glynn

Project Summary: This 7-year randomized controlled trial seeks to measure the comparative effectiveness of newer diabetes medications in preventing cardiovascular and kidney disease among patients with type 2 diabetes. Additionally, researchers want to learn about serious side effects in the treatment groups and their effect on patients’ quality of life. Patient outcomes, tracked through electronic health records and patient reports, will contribute to new understandings to guide patients and providers as they decide which diabetes medications are best for patients.

Study Design: Multi-CRN Data only Observational

Sponsor: PCORI®

The PRECIDENTD study is a PCORnet® Study conducted using PCORnet®, the National Patient-Centered Clinical Research Network, an initiative funded by the Patient-Centered Outcomes Research Institute (PCORI). More information about PCORnet® can be found here.

The PRECIDENTD study was funded by PCORI through PCORI Award (PLACER-2020C3-21005).

The statements presented on this website are solely the responsibility of the author(s) and do not necessarily represent the views of other organizations participating in, collaborating with, or funding PCORnet or of PCORI.

Coordinating Center: Brigham and Women’s Hospital